FGF21 and obesity due to melanocortin 4 receptor deficiency: Given the potential of FGF21 as a therapeutic target against metabolic disorders such as obesity and diabetes (Giralt et al., 2015; Strowski, 2017), these results could have promising clinical implications, being RT the most recommended training mode for the stimulation of FGF21.